New advances in hepatocellular carcinoma

Table 3 Summary of the characteristics of the published studies including patients within Milan criteria or with expanded criteria

Ref.	Patients MC/EC	HCC criteria	Staging method	Design	5-yr survival (%) MC/EC
Yao et al[158] UCSF criteria	46/14	1 < 6 cm	Explant	Retro	72
		2-3 > 4, 5 cm
		Sum diameter < 8 cm
Herrero et al[154] Navarra Criteria	35/12	1 < 6 cm	Rx	Pros
		2-3 < 5 cm
Kneteman et al[157]	19/21	1 < 7.5 cm	Explant	Pros	87/83 (4-yr)
	18/9	Multinodular < 5 cm	Rx		92/77
Yao et al[152]	130/38	1 < 6 cm	Rx	Pros	90/93
		2-3 > 4, 5 cm
		Sum diameter < 8 cm
Silva et al[159] Valencia Criteria	231/26	1 < 5 cm	Explant	Retro	62/69
	254/27	2-3 < 5 cm	Rx
		Sum diameter 10 cm
Herrero et al[156]	59/26	1 < 6 cm	Explant	Pros	70/56
		2-3 < 5 cm	Rx		66/68
Mazzaferro et al[155] Metroticket	444/283	Sum nodules/size	Explant	Retro	73/71
		7 cm
Fan et al[160] Shanghai Criteria	394/176	1 < 9 cm	Explant	Retro	51/65
		2-3 < 5 cm
		Sum diameter 9 cm
Guiteau et al[161]	363/82	1 < 6 cm	Rx	Pros	73/71 (3-yr)
		2-3 < 5 cm
		Sum diameter 9 cm

Staging method: Pre LT with radiological features (Rx) or post LT according to histopathological features (Explant). Study design: retrospective (Retros), prospective (Pros). MC: Milan criteria; EC: Expanded criteria; LT: Liver transplant; UCSF: University of California, San Francisco; HCC: Hepatocellular carcinoma.